For decades, the performance of medical devices has been defined largely by their form and mechanical design. Now, a generation of ‘smart materials’ is redefining what these devices can do. But what are the fundamental characteristics that define these materials for biomedical application? Professor Ipsita Roy, deputy director of research and innovation at the University of Sheffield’s School of Chemical, Materials and Biological Engineering explains; “Smart Materials are those that are responsive to external stimuli such as temperatures and fatigue resistance.”
Smart and functional materials – engineered to sense, respond and adapt to their surroundings – are emerging as a transformative force in healthcare technology. Self-healing polymers that repair microscopic fractures without intervention, nickel-titanium alloys that change shape on cue and hydrogels that release drugs in response to precise triggers are no longer the stuff of speculative research. They are advancing rapidly towards clinical application.
These innovations are not incremental. They promise to extend device lifetimes, reduce surgical interventions and deliver therapies with unprecedented precision. Yet, their path to the operating theatre is far from straightforward. Sterilisation compatibility and high-volume manufacturing remain formidable hurdles. The challenge is not simply to invent these materials, but to integrate them into industrial workflows without losing the properties that make them extraordinary.
The material evolution
Self-healing polymers illustrate both the potential and the complexity of this new frontier. Designed to restore structural integrity after sustaining damage, they can extend the life of implants and wearable systems. Some achieve this through embedded reservoirs of reactive agents that polymerise when a crack forms; others rely on reversible chemical bonds that reform under specific conditions. In the lab, the effect is striking; microfractures vanish, restoring strength with minimal loss of performance. In the body, the implications are significant. Orthopaedic implants, cardiovascular components, or even soft robotic surgical tools could repair themselves, reducing the risk of sudden failure.
But performance in a controlled environment is only half the equation. Before they reach a patient, all medical devices must be sterilised – often via highpressure steam, radiation or chemical agents. These processes are harsh. Heat can break the very bonds that enable self-healing. Radiation can alter polymer microstructures, rendering them brittle.
Chemical sterilant may leave residues that interfere with healing chemistry. While a handful of polymer systems have been engineered to survive such treatment, they remain exceptions. Until these materials can endure sterilisation without degradation, their use in long-term or load-bearing devices will remain limited. If self-healing polymers aim to make devices more resilient, shape-memory alloys focus on making them more adaptable. Nitinol (NiTi), an alloy of nickel and titanium, is the most widely known example. Its ability to change shape in response to temperature – or recover from large deformations without permanent damage – has transformed the design of stents, filters and surgical instruments.
“The transformation temperature of NiTi can be controlled by the addition of third elements such as niobium, copper and iron,” Roy explains. “NiTi fatigue resistance can be controlled by changing internal material properties, the manufacturing processes used and external conditions.”
Delivered in a compact form, these devices expand, or shift shape once deployed in the body, often with remarkable precision. This property is the result of a reversible transformation between two crystal phases, tuned so that the change occurs within the narrow range of human body temperature. Recent advances in additive manufacturing have broadened the design possibilities for NiTi devices. Techniques such as laser powder bed fusion now allow engineers to create complex, patient-specific geometries directly from digital models, reducing material waste and post-processing. As well as this, “internal properties can be changed by processing methods like precipitation and grain refinement, which can significantly improve fatigue life. External factors could involve thermomechanical treatment and cyclic loading conditions, which can also improve fatigue life,” Roy shares.
However, these methods also introduce new challenges. Microstructural variations, inclusions and surface roughness can compromise fatigue resistance, an essential consideration for implants subjected to millions of loading cycles. Electropolishing and other finishing processes can restore surface quality but add time and cost. Sterilisation is a similarly delicate issue. Nitinol’s corrosion resistance and biocompatibility rely on a stable oxide layer. Certain sterilisation methods can disrupt this layer, increase nickel ion release and potentially trigger adverse reactions. Managing these effects without compromising device function is a balancing act, particularly when scaling production for global markets.
Stimuli-responsive hydrogels offer yet another approach to “enhance mechanical properties”, Roy explains. “Smart hydrogels can incorporate sensors for continuous monitoring of various physiological indicators and biomarkers, as well as having adaptive drug release.”
Temperature-sensitive hydrogels might release a drug when exposed to a mild fever; pH-sensitive variants could deliver chemotherapy directly to the acidic microenvironment of a tumour. Some formulations are injectable, flowing into irregular anatomical spaces before solidifying into a functional form. Others serve as scaffolds for tissue engineering, supporting cell growth and gradually degrading as new tissue forms.
Such versatility is unmatched by conventional materials, but so are the manufacturing constraints. Hydrogels’ high water content makes them vulnerable to drying, swelling or structural collapse during sterilisation. Steam can alter their network structure; radiation may trigger unwanted chemical reactions; and chemical sterilant can be hard to remove without damaging the gel. Emerging techniques such as supercritical carbon dioxide processing may preserve function more effectively, but they are not yet standard in medical manufacturing. For now, most commercial hydrogel devices are designed for single use or environments where sterilisation demands are minimal.
Evidently, the possibilities are endless, with smart materials evolving at a rapid pace, as echoed by Roy: “There are many developments in this area, so it is difficult to point out which are most promising.” However, promising examples of stimuli-responsive materials being developed also include “materials like azobenzene-based polymers and spiropyrans, mixed polymer brushes and liquid crystal elastomers”.
Looking ahead
Across these material classes, a pattern emerges. Laboratory prototypes perform impressively under controlled conditions but translating them into viable products means aligning their unique behaviours with the rigorous, standardised processes of medical device production. High-throughput moulding, extrusion and assembly lines are optimised for traditional materials whose properties remain stable under heat, pressure and sterilisation. Smart materials, by definition, are designed to change – an attribute that complicates manufacturing. Regulatory requirements amplify this challenge. Approval agencies require extensive data showing that a device will perform safely and predictably after sterilisation, during storage and throughout its intended lifespan in the body. For materials designed to respond dynamically to their environment, this means long-term studies to confirm that responsiveness is maintained, degradation products are benign, and so unintended changes occur under physiological conditions. Such studies can span years, demanding significant investment before a product reaches market.
The cultural conservatism of the medical device industry adds a further layer of inertia. Manufacturers operate in a high-stakes environment where reliability and compliance take precedence over novelty. Even a small degree of uncertainty can be enough to stall adoption, particularly if alternative materials already meet regulatory and performance requirements. Innovators in smart materials are therefore increasingly seeking hybrid approaches – combining novel components with conventional substrates or architectures to ease integration and reduce perceived risks. Despite these barriers, the trajectory of research and early commercialisation is promising. Functional materials are already finding niches in devices where their advantages outweigh the integration challenges. Roy remains cautiously optimistic and shares her views, explaining: “In general, it is the investment in innovative materials that is lacking.
“All commercial enterprises want economic security, hence are always hesitant to provide the money and time required for the data acquisition required for obtaining FDA approval.” In the years ahead, incremental progress in both material resilience and manufacturing processes could unlock broader adoption, but that’s only possible with investment.
Self-healing polymers might be encapsulated in protective coatings that can withstand autoclaving. NiTi devices could be surface engineered to retain corrosion resistance after sterilisation. Hydrogels might be cross-linked using chemistries designed to tolerate irradiation without losing responsiveness. Advances in sterilisation technology itself may also play a role. As more devices incorporate sensitive materials, demand will grow for methods that are both rigorous and gentle – capable of eliminating microbial risk without damaging delicate molecular structures. Techniques once considered niche could become mainstream, enabling a wider range of material options for device designers.
The implications extend beyond individual devices. Smarter materials could reduce the need for repeat surgeries, lower long-term healthcare costs, and enable entirely new therapeutic strategies. Imagine cardiovascular implants that respond to early signs of restenosis by releasing targeted drugs, orthopaedic components that repair themselves after stress fractures or wound dressings that alter their permeability in response to infection. These are not distant visions; prototypes exist, and early studies are building the evidence base for clinical use.
Ultimately, the story of smart materials in medical devices is one of integration. The scientific breakthroughs are already happening. The next challenge is ensuring they survive the transition from lab bench to production line, retaining their functionality after the rigours of manufacturing and sterilisation. For the companies that succeed, the reward will be devices that are not only safer and more effective, but also more aligned with the dynamic, adaptive nature of the human body.
Nitinol’s shape-memory superpower
Nitinol, a near-equiatomic alloy of nickel and titanium (NiTi), is the workhorse of shape-memory and superelastic materials in medical device engineering. Its ability to return to a pre-set shape upon encountering body temperature makes it invaluable for life-changing implant applications. A recent clinical review highlighted how nitinol’s shape-memory effect empowers self-expandable stents, which are crimped in the martensite phase (below transformation temperature) and, once deployed in the body, naturally expand and conform to vessel walls as they re-enter the austenite phase.
“Nitinol is an equiatomic alloy of nickel and titanium. Its unique properties like ‘superelasticity’ and ‘shape memory’ have made it one of the most commonly used materials for manufacturing hardware in endovascular neurosurgery. The solid state of nitinol has two interconvertible (austenite and martensite) phases. With increasing temperature, the martensite phase gets transformed into the austenite phase (thermal phase transformation), and thus remembers the shape.”
Source: ‘NiTinol: A Review of Its Smart Properties That Make It a Smart Alloy and a Strong Ally in Endovascular Neurosurgery’
